The global IV bag market is valued at US$ 3.10 billion in 2026 and is projected to reach US$ 5.56 billion by 2033, growing at a CAGR of 9.5%.
Market growth is driven by rising post-surgical procedures, expanding chronic disease management programs, and increasing long-term IV therapy utilization.
Normal Saline leads with a 42.8% share due to its universal compatibility with injectable medications and widespread use across healthcare settings.
North America dominates with a 41.6% market share, supported by advanced healthcare infrastructure and a well-established home infusion therapy ecosystem
Leading players include Baxter International, B. Braun, and Fresenius Kabi, operating in a moderately consolidated yet highly competitive market.